Top 5 Target	Count

IFNAR(Interferon alpha/beta receptor)	5
HER2(Receptor tyrosine-protein kinase erbB-2)	2
TNF-α(Tumor necrosis factor α)	2
PDL1(Programmed death-ligand 1)	1
IFNAR x Nav1.8	1

Drugs associated with Danaher Corp.

Empegfilgrastim

Target

CSF-3R

Mechanism

CSF-3R agonists

Active Org.

Originator Org.

Active Indication

Inactive Indication

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

India [+2]

First Approval Date01 Jun 2016

Cepeginterferon alfa-2b

Target

IFNAR

Mechanism

IFNAR agonists [+2]

Active Org.

Biocad Medical, Inc.

Originator Org.

Biocad Medical, Inc.

Active Indication

Hepatitis C

Inactive Indication

Hepatitis C, Chronic [+1]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

Russia

First Approval Date01 Dec 2013

Odulimomab

Target

CD11a

Mechanism

CD11a antagonists

Active Org.-

Originator Org.

Immunotech

Active Indication

Graft vs Host Disease [+1]

Inactive Indication

Delayed Graft Function

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

France

First Approval Date01 Jan 1997

103

Clinical Trials associated with Danaher Corp.

NCT03767231

/ Not yet recruitingNot ApplicableIIT

Emergency Department Patient's Perceptions and Acceptability Toward a Novel Point-of-Care Hepatitis C Virus Viral Load Testing

Hepatitis C virus (HCV) infection has become the leading fatal infectious disease in the United States. Approximately 75% of individuals who have been infected with HCV are chronically infected with the virus. Untreated chronic infection will lead to severe sequelae such as cirrhosis and hepatocellular carcinoma. Even though the availability of rapid HCV antibody (HCV Ab) screening assay and highly effective antiviral treatment, most people infected with HCV are not aware of the infection status. This gap mainly comes from the current gold standard confirmatory testing for chronic HCV infection, the Polymerase Chain Reaction (PCR)-based HCV RNA viral load assay which requires an experienced trained laboratory technician to perform relatively complicated PCR assay with a turn-around-time of 1 to 2 days (from provider's order to the test resulting). The investigators' rapid HCV Screening and Linkage to Care program has demonstrated that many patients in the investigators' emergency department (ED) are unaware of patient's chronic HCV infection status due to the barriers to receive the gold standard viral load testing.
Recently, a novel Xpert HCV Viral Load (VL) Finger-stick (FS) [Xpert HCV VL FS] point-of-care (POC) test (Cepheid) has been developed. In an observational cohort in Australia, HCV RNA was detected in 40% of participants (85 of 210) enrolled at 3 drug treatment clinics and 1 homelessness service. Sensitivity of the Xpert HCV VL FS assay for HCV RNA quantification in samples collected by finger-stick was 100.0% (95% Confidence Interval (CI), 93.9%-100.0%) and specificity was 100.0% (95% CI, 96.6%-100.0%). The Xpert HCV VL FS test can accurately detect active infection from a finger-stick sample in 1 hour allowing single-visit HCV diagnosis.
In this protocol, the investigators seek to determine the needs and acceptability of a novel POC HCV viral load testing assay among ED HCV Ab positive patients. For this project, the investigators will identify and enroll ED patients with HCV Ab positive but without HCV viral information. The investigators will conduct a randomized study to assign eligible and consented patients to either to POC Testing Group or Standard of Care (SOC) Group. All participants will take a short survey regarding HCV care and treatment. As part of the investigators' ED HCV Screening and Linkage to Care Program, all participants will receive the standard-of-care clinical laboratory-based HCV RNA viral load testing via whole blood (i.e. patient will receive blood drawn). This standard-of-care HCV viral load testing result will be provided to participant when it is available (usually 1-2 days later). Participants in the POC Testing Group will receive the novel POC HCV RNA viral load testing and the result of the novel test will be disclosed to the patients approximately within 2 hours of the testing. Linkage to care information after the ED visit will be compared between two groups. Finally, accuracy of this POC HCV RNA viral load testing in the acute care setting will be determined as compared to the standard-of-care clinical laboratory-based HCV RNA viral load testing. The investigators will also ask all of participants to grant permission to use the remnant blood specimens for an evaluation of future in-house HCV RNA viral load assay.

Start Date01 Nov 2025

Sponsor / Collaborator

The Johns Hopkins University

[+1]

NCT06885528

/ Not yet recruitingNot Applicable

UniCel DxH 900/690T Monocyte Distribution Width (MDW) Dual Cut-Off Clinical Accuracy Protocol

This study will establish the clinical performance of the Monocyte Distribution Width (MDW) parameter on the DxH 900/ DxH 690T hematology analyzers to aid in the detection and risk assessment of patients in the Emergency Department (ED) for progression to sepsis.

Start Date01 May 2025

Sponsor / Collaborator

Beckman Coulter, Inc.

[+3]

NCT06669286

/ Not yet recruitingNot Applicable

Retrospective Single Cohort Mono-center Study on Success and Safety of Navigated Implant Placement in Proximity of the Alveolar Nerve

Subjects with severely atrophic mandibles were treated with implants and implant-based restorations. Subjects will be required to consent to study participation and data processing according to General Data Protection Regulation (GDPR). Implant positions were planned digitally in a dental software DTX Studio, and implants placed with navigated surgery (Nobel Biocare X-Guide). Implants eligible for this study must be placed 2 mm or less from the alveolar nerve. Implants placed are NobelParallel TiUnite and NobelActive TiUnite. All subjects were followed up for 1 year after surgery to monitor success and adverse events related to the alveolar nerve. Data analysis will include demographics, medical history, Cone-beam Computed Tomography (CBCT) scans/peri-apical x-ray data, soft tissue parameters, and adverse events.

Start Date31 Dec 2024

Sponsor / Collaborator

CLINICA ODONTOIATRICA VILLA S.R.L.

[+1]

100 Clinical Results associated with Danaher Corp.

0 Patents (Medical) associated with Danaher Corp.

3,570

Literatures (Medical) associated with Danaher Corp.

31 Dec 2025·Emerging Microbes & Infections

Monocyte distribution width (MDW) as a reliable diagnostic biomarker for sepsis in patients with HIV

Article

Author: Sun, Jianjun ; Qi, Tangkai ; Jiang, Rui ; Chen, Jun ; Xu, Shuibao ; Shen, Yinzhong ; Zhang, Renfang ; Tang, Yang ; Shao, Yueming ; Liu, Li ; Tang, Yi-Wei ; Xun, Jingna ; Wang, Xialin ; Yang, Junyang ; Wang, Zhenyan ; Sun, Jinfeng ; Chen, Youming ; Song, Wei ; Qian, Liu ; Lu, Hongzhou

Sepsis is a leading cause of death among patients with HIV, but early diagnosis remains a challenge. This study evaluates the diagnostic performance of monocyte distribution width (MDW) in detecting sepsis in patients with HIV. A prospective observational study was conducted at Shanghai Public Health Center, involving 488 hospitalized patients with HIV aged 18-65 between December 2022 and August 2023. MDW was measured at admission, and its diagnostic accuracy was compared with Sepsis-3 criteria. Survival rates on day 28 and 90 were also recorded. Additionally, five machine learning (ML) models were tested to enhance diagnostic efficacy. Of 488 subjects, 90 were in the sepsis group and 398 in the control group. MDW showed a diagnostic area under the curve (AUC) of 0.82, comparable to C-reactive protein (CRP) and Procalcitonin (PCT) with AUCs of 0.78 and 0.82, respectively. With a cut-off value of 25.25, MDW had a sensitivity of 0.83 and specificity of 0.76. The positive and negative predictive values were 44% and 95%, respectively. When MDW was combined with platelet count, serum albumin, and hemoglobin in a random forest model, the AUC improved to 0.931. The model achieved a sensitivity of 1.00 and specificity of 0.732. MDW is a useful diagnostic marker for sepsis in patients with HIV, with strong sensitivity and specificity. Combining MDW with other lab markers can further enhance diagnostic accuracy.Trial registration: ClinicalTrials.gov identifier: NCT05036928..

01 Jun 2025·Journal of Pharmaceutical and Biomedical Analysis

Guilty by dissociation: Part C: Enantiomeric separation of diphenidine-derived new psychoactive substances (NPS) by polar organic chiral high performance liquid chromatography (HPLC) on polysaccharide-based stationary phases

Article

Author: Farkas, Tivadar ; Sallenger, Michael A ; Sutcliffe, Oliver B ; Barrett, Benjamin S ; Euerby, Melvin R ; Costello, Andrew

This study describes a simple and practical HPLC analysis for the direct enantiomeric separation of a range of 32 novel diphenidine derived psychoactive substances using a range of six polysaccharide-based chiral stationary phases employing a single generic polar organic solvent chromatographic mobile phase. Temperature was employed to optimize the chemo and enantiomeric selectivity. Baseline separation and differentiation of both the enantiomers and positional isomers (i.e., regioisomers) of the 2-, 3- and 4-methoxphenidines was achieved with the chiral selector cellulose tris(3-chloro-4-methylphenylcarbamate) coated onto silica. The latter proved to be the best of the six chiral stationary phases investigated in that it generated enantiomeric separation of 25 of the 26 monosubstituted diphenidines with resolution values > 1.5. It yielded the optimum separation for 21 of the 26 diphenidines (resolution values ranged from 2.9 - 22.4) including the 2-, 3- and 4-positional isomers of eight diphenidine derivatives. Excellent separation of all 26 monosubstituted diphenidines (i.e., resolution values > 1.5) and peak shape (i.e., typical tailing factors between 0.9 - 1.2) could be achieved by using Lux Cellulose-2 and Lux i-Amylose-3 columns. The nature of the polysaccharide-based chiral selector was demonstrated to be extremely important in determining the degree of chiral resolution. The location of the monosubstituent on the 1-phenyl ring of the diphenidine was shown to be important in promoting chiral resolution. Greater chiral discrimination was typically observed for substituents in the 4-position compared to those in the 2-position of the 1-phenyl ring. The chiral HPLC methodology displayed good chemo and enantiomeric selectivity of the mono-, di- and trisubstituted diphenidine regioisomers. Enantiomer elution order reversal was highlighted with 2-methoxphenidine enantiomers as a function of the chiral stationary phase. The (R)-enantiomer eluted before the (S)-enantiomer on cellulose-based chiral stationary phase whereas the reverse occurred with the amylose-based phases. Application of the methodology to the analysis of real-life samples of 2-methoxphenidine and diphenidine confirmed that these psychoactive substances were being traded as racemic products. Commonly used adulterants in powdered samples were shown not to interfere with the chiral analysis of 2-methoxphenidine and diphenidine.

01 May 2025·Advances in Therapy

Point of Care Nucleic Acid Testing for Influenza-Like Illness: A Cost–Consequence Analysis for High-Risk Patients in Primary Care in Germany

Article

Author: Pollock, Richard F ; Chase, Jordan ; Wittki, Tanja ; Brown, Tray ; Joecker, Anika ; Pöhlmann, Johannes

INTRODUCTIONInfluenza A/B virus, severe acute respiratory coronavirus 2 (SARS-CoV-2), and respiratory syncytial virus (RSV) cause similar symptoms, often referred to as influenza-like illness, but require different treatments which must be administered within a short timeframe after symptom onset. This necessitates rapid detection and accurate differentiation by primary care providers, ideally at point of care (POC). POC nucleic acid tests such as the multiplex, real-time polymerase chain reaction (PCR) Xpert^® Xpress CoV-2/Flu/RSV plus (Xpert Xpress) offer a faster, more accurate alternative compared to antigen testing, clinical judgement alone, or send-out PCR. This cost-consequence analysis evaluated Xpert Xpress versus conventional testing methods, from a German statutory health insurance (SHI) perspective.METHODSA 1-year decision tree was developed to compare Xpert Xpress with antigen testing, send-out PCR, and empiric diagnosis, for influenza A/B virus, SARS-CoV-2, and RSV. The model accounted for diagnostic accuracy and projected the share of patients receiving results within guideline-recommended treatment windows. Data on test accuracy, treatment effects, and costs were sourced from literature and German databases. The main outcome was total cost to the SHI for the 2023/24 respiratory illness season.RESULTSXpert Xpress was associated with the highest number of net correct treatment courses (n = 443,600) versus empiric diagnosis (n = 239,250), antigen testing (n = 347,218), and send-out PCR (n = 280,527). Acquisition costs were highest for Xpert Xpress (EUR 38.4 million versus EUR 27.4 million for antigen testing and EUR 33.5 million for send-out PCR) but were offset by reduced hospitalization and intensive care costs. Overall, Xpert Xpress was associated with cost savings of EUR 1.97 million versus empiric diagnosis, EUR 10.1 million versus antigen testing, and EUR 20.8 million versus send-out PCR.CONCLUSIONSUsing Xpert Xpress at POC combined fast turnaround with high diagnostic accuracy, thereby increasing correct treatment courses while reducing total costs for influenza, COVID-19, and RSV, offering substantial savings to the German SHI.

1,208

News (Medical) associated with Danaher Corp.

01 May 2025

·www.prnewswire.com

In Vitro Diagnostics: Technologies Transforming Global Healthcare Markets

" In vitro diagnostics (IVD) refers to tests performed outside the body to detect diseases, monitor health, or guide treatments. These technologies are revolutionizing global healthcare by enabling early diagnosis, personalized medicine, and improved patient outcomes. " BOSTON, May 1, 2025 /PRNewswire/ -- According to the latest study from BCC Research, In Vitro Diagnostics: Technologies and Global Markets is projected to grow from $94.7 billion in 2024 to $141.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 8.4% during the forecast period of 2024 to 2029.Boston: According to the latest study from BCC Research, In Vitro Diagnostics: Technologies and Global Markets is projected to grow from $94.7 billion in 2024 to $141.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 8.4% during the forecast period of 2024 to 2029. This report analyzes in vitro diagnostic (IVD) technologies and devices used in hospitals and point-of-care (POC) settings, focusing on market trends, drivers, opportunities, and competitive intelligence. It segments the market by technology, application, end user, and region, with forecasts through 2029. Interesting facts: Artificial Intelligence (AI) has revolutionized the healthcare industry. The report explores how companies are integrating AI into IVD devices. POC testing is increasingly used over traditional hospital and clinic-based diagnostics, with demand surging post-pandemic. Haematology remains a widely practiced test type compared to diagnostic microbiology, driven by a global rise in blood-related disorders. Factors contributing to the market's growth include: Rise in the population of older adults and dependency on frequent diagnosis procedures : The growing number of older adults is increasing the need for frequent diagnostic procedures to manage age-related health conditions. This trend is driving demand for advanced and accessible diagnostic solutions. Integration of artificial intelligence in IVD : AI is being integrated into in vitro diagnostics to improve the accuracy and speed of disease detection. This technology helps provide more personalized and efficient healthcare solutions. Rising incidence of chronic diseases: The rising incidence of chronic diseases, such as diabetes and heart conditions, is increasing the need for ongoing monitoring and diagnostic tests. This trend is fueling the demand for advanced diagnostic technologies. Improving the quality of POC testing: This is making health diagnostics faster, more accurate, and easily accessible, especially in remote or urgent care settings. Request a Sample Copy of the In Vitro Diagnostics: Technologies and Global Markets Report Synopsis Questions A ddressed: What is the projected market size and growth rate? The market is projected to grow from $87.8 billion in 2023 to $141.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 8.4% during the forecast period. What are the factors driving the growth of the market? Rise in the aging population and dependency on frequent diagnosis procedures, Integration of AI in IVD, rising incidence of chronic diseases and improving the quality of POC testing. What market segments are covered in the report? The market is segmented by technology, application and end user. Which technology segment will be dominant over the forecast period? The haematology segment is anticipated to dominate the market through the end of 2029. Which region has the largest market share? North America holds the largest market share. Market leaders include : Abbott Becton, Dickinson and Co. Biomerieux Bio-Rad Laboratories Inc. Bio-Techne Bruker Danaher Corp. EKF Diagnostics Holdings Plc F. Hoffmann-La Roche Ltd. Hologic Inc. JSR Corp. Quidelortho Corp. Siemens Healthineers AG Sysmex Corp. Thermo Fisher Scientific Inc. Related reports include: In Vitro Diagnostics (IVD) Quality Controls: Global Market: The global market for in vitro diagnostics (IVD) quality controls focuses on ensuring the accuracy and reliability of diagnostic tests. As demand for precise diagnostics grows, the need for high-quality control systems in IVD devices is growing worldwide. In Vitro Diagnostics (IVD) Analyzers: Global Market : The global market for IVD analyzers is driven by the rising demand for efficient and accurate diagnostic testing. These analyzers play a crucial role in disease detection and monitoring. Purchase a copy of the report direct from BCC Research. For further information on these reports or to purchase one, please contact [email protected]. About BCC Research BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help readers make informed business decisions, free of noise and hype. Contact Us Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USA Email: [email protected] Phone: +1 781-489-7301 For media inquiries, email [email protected] or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. Logo: SOURCE BCC Research LLC WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Diagnostic Reagents

28 Apr 2025

·www.prnewswire.com

CS Genetics Appoints Paul McEwan as Independent Board Director

SAN DIEGO, April 28, 2025 /PRNewswire/ -- CS Genetics, a leader in single cell genomics, is proud to announce the appointment of Paul McEwan as an Independent Director to its Board. Mr. McEwan brings over two decades of experience in life science tools, genomics, and strategic growth. Mr. McEwan is a serial entrepreneur in the life sciences sector, with a proven track record of founding and scaling innovative biotech companies. He co-founded Kapa Biosystems, serving as Chief Scientific Officer from 2006 until its acquisition by Roche in 2015. Under his leadership, Kapa Biosystems pioneered the use of directed evolution to develop high-performance reagents for life science applications. In addition to Kapa Biosystems, Mr. McEwan co-founded Agencourt Bioscience and Agencourt Personal Genomics. These ventures collectively achieved an exit value of over $700 million, underscoring his ability to generate significant commercial and financial returns from venture-stage life-science companies. Beyond his entrepreneurial ventures, Mr. McEwan is an active angel investor, focusing on early-stage companies in life science tools and diagnostics. He currently serves as Chairman of DNA Script and SeqWell, and as a Board Member of Watchmaker Genomics, Oligo Factory and Codetta Bio. "We are thrilled to welcome Paul to our Board of Directors," said Bill Colston, CEO of CS Genetics. "His extensive experience in genomics and strategic growth will be invaluable as we continue to advance our mission of democratizing single cell genomics." About CS Genetics CS Genetics is a privately held genomics-technology company based in San Diego, California. The company has developed a radically new, instrument-free platform for single-cell genomics with disruptive simplicity, speed, and scalability that will launch a new era of NGS-based cellular analysis. The company's technology leverages a molecular process known as Kinetic Confinement that is categorically different to other single cell technologies, and plugs seamlessly into standard, widespread lab infrastructure. The company holds a large global intellectual property estate covering its single cell platform and related reagent, workflow, manufacturing and application technologies. For more information, visit . Media Contact: Matt Browning Director of Marketing CS Genetics, Inc. [email protected] SOURCE CS Genetics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Executive ChangeAcquisition

22 Apr 2025

·endpts.com

Danaher expects about $350M in tariff costs; Alumis, Acelyrin adjust deal terms

Plus, news about Invivyd: Danaher’s tariffs hit: The life sciences company currently expects the costs of tariffs to be “something like $350 million” in 2025, according to CEO Rainer Blair on Tuesday’s earnings call. Danaher also told investors that it may be able to offset the impact by making changes to the supply chain and manufacturing, surcharges and “other cost actions.” — Jaimy Lee Alumis, Acelyrin amend merger terms: The updated agreement calls for Acelyrin shareholders to get an increased ownership stake of about 48%. Alumis shareholders will own about 52% of the combined company, down from 55% originally. The two biotechs agreed to merge in February, and Acelyrin last month rejected a takeover bid from Kevin Tang’s Concentra Biosciences. — Max Gelman Invivyd’s $30M loan: The money comes in the form of a loan facility with Silicon Valley Bank, available in three $10 million tranches depending on certain milestones, according to an SEC filing . CFO Bill Duke said that the loan comes ahead of regulatory discussions with the FDA over an experimental Covid-19 antibody called VYD2311. — Max Gelman

Acquisition

100 Deals associated with Danaher Corp.

100 Translational Medicine associated with Danaher Corp.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 14 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

Preclinical

Phase 1 Clinical

Phase 2 Clinical

Phase 3 Clinical

Approved

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Bevacizumab biosimilar(Biocad Medical, Inc.) ( VEGF-A )	Glioblastoma More	Approved
Cepeginterferon alfa-2b ( IFNAR )	Hepatitis C More	Approved
Interferon beta-1a biosimilar(Biocad Medical, Inc.) ( IFNAR )	Multiple Sclerosis More	Approved
Interferon alfa-2b/Taurine/Benzocaine ( IFNAR x Nav1.8 )	Human Papillomavirus Infection More	Approved
Trastuzumab biosimilar(Biocad Medical, Inc.) ( HER2 )	Breast Cancer More	Approved

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis